Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TC-NK
- Development stage
- Unknown
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TC-NK is a therapeutic cell product composed of purified natural killer (NK) cells. It is designed for use in haploidentical donor hematopoietic cell transplantation (HCT) for individuals diagnosed with high-risk hematologic malignancies. The product is derived from donor peripheral blood stem cells, which undergo G-CSF mobilization and apheresis collection, followed by purification to isolate the natural killer cells.
- Other names
- purified natural killer cells
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)MICB (Major histocompatibility complex class i-related protein B)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on TC-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TC-NK.